Asian race and origin have no clinically meaningful effects on polatuzumab vedotin pharmacokinetics in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
Rong ShiTong LuGrace KuHao DingTomohisa SaitoLeonid GibianskyPriya AgarwalXiaobin LiJin Yan JinSandhya GirishDale MilesChunze LiDan LuPublished in: Cancer chemotherapy and pharmacology (2020)
Race has no clinically meaningful effect on pola PK. These results (and observations from efficacy/safety exposure-response analyses) support no pola dose adjustments are warranted for Asian patients with DLBCL.